A Study to Evaluate Droperidol Use in the Emergency Department and the Effect on QTc


About this study

The purpose of this study is to study the length of the QTc interval in patients receiving the standard of care dose of intravenous droperidol for headache or migraine, nausea, pain, and indications other than agitation over 30 minutes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Adults and children 12 years of age or older.
  • Patients receiving droperidol in the ED on the cardiac monitor for indications other than agitation.

Exclusion Criteria:

  • Patient receiving droperidol for agitation.
  • Patients under 12 years of age.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

M. Fernanda Bellolio, M.D.

Contact us for the latest status

Contact information:

Maria Fernanda Bellolio Avaria M.D.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer